Chiesi Announces Results of the Tanimilast Phase III PILASTER Clinical Study in Chronic Obstructive Pulmonary Disease (COPD)
published by: Chiesi Farmaceutici S.p.A.
Category:Innovation
Chiesi Group today announced the results of the tanimilast Phase III PILASTER clinical study in Chronic obstructive pulmonary disease (COPD). The study did not meet its primary and secondary endpoints. There were no safety signals observed during the study.
The company would like to thank the internal teams, all the investigators and patients involved in the study for their partnership and commitment during the study. The quality of their work and excellence have been truly outstanding throughout this program.
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
